FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis
FOS is a target of DYX for the treatment of MI, and the mechanism of action may be related to the modulation of immune infiltration.
Authors
- Lin Wang (ORCID: https://orcid.org/0000-0002-3557-1853)
- Shiyi Liu (ORCID: https://orcid.org/0000-0001-7114-7518)
- Junfeng Fang (ORCID: https://orcid.org/0000-0003-4235-4520)
- Wei Wu (ORCID: https://orcid.org/0000-0001-8911-6920)
- Weifeng He (ORCID: https://orcid.org/0000-0001-7131-7003)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fcvm.2025.1488684
- Primary Topic
- Viral Infections and Immunology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00